DelNova

United States
Illinois City, Illinois, United States, 60035

Company profile

DelNova company profile

DelNova is developing proprietary therapies by leveraging advances in drug delivery technology. They have identified an anticholinesterase class of drugs as a means of accelerating muscle recovery by indirectly increasing the neurotransmitter deficit caused by botulinum toxin.

Business identity

Operating status
Active
Company type
For Profit
Employee range
11-50 employees
Revenue range
$0-$1M
Founded
2016-01-01, Year

Headquarters

Postal code
60035
Country code
US
Continent
North America

Capital profile

Funding and company signals

Funding rounds
1
Total equity funding
$810,246
Last funding
Series Unknown / $810,246 / 2018-04-02
Last equity funding
Series Unknown / $810,246
Founders
1

Founders and investors

Founders

Mary Gardner